Publications

Found 1 results
Filters: Author is S.Q. Li  [Clear All Filters]
2012
J. N. Zhang, Yi, S. H., Zhang, X. H., Liu, X. Y., Mao, Q., Li, S. Q., Xiong, W. H., Qiu, Y. M., Chen, T., and Ge, J. W., Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma, vol. 11, pp. 3618-3628, 2012.
Bai J, Dai J, Yu H, Shen H, et al. (2009). Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J. Toxicol. Environ. Health A 72: 677-682. http://dx.doi.org/10.1080/15287390902840930 PMid:19492228   Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. http://dx.doi.org/10.2307/2533446 PMid:7786990   Biernat W, Kleihues P, Yonekawa Y and Ohgaki H (1997). Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56: 180-185. http://dx.doi.org/10.1097/00005072-199702000-00009 PMid:9034372   Bond GL, Hu W, Bond EE, Robins H, et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. http://dx.doi.org/10.1016/j.cell.2004.11.022 PMid:15550242   Bredel M, Scholtens DM, Yadav AK, Alvarez AA, et al. (2011). NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364: 627-637. http://dx.doi.org/10.1056/NEJMoa1006312 PMid:21175304   Dai S, Mao C, Jiang L, Wang G, et al. (2009). P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638. http://dx.doi.org/10.1007/s00439-009-0664-3 PMid:19357867   DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188. http://dx.doi.org/10.1016/0197-2456(86)90046-2   Dumont P, Leu JI, Della Pietra AC, George DL, et al. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365. http://dx.doi.org/10.1038/ng1093 PMid:12567188   Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. http://dx.doi.org/10.1136/bmj.315.7109.629 PMid:9310563 PMCid:2127453   El Hallani S, Marie Y, Idbaih A, Rodero M, et al. (2007). No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J. Neurooncol. 85: 241-244. http://dx.doi.org/10.1007/s11060-007-9416-1 PMid:17568997   El Hallani S, Ducray F, Idbaih A, Marie Y, et al. (2009). TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 72: 332-336. http://dx.doi.org/10.1212/01.wnl.0000341277.74885.ec PMid:19171829   Fang F, Yu XJ, Yu L and Yao L (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med. Oncol. 28: 981-985. http://dx.doi.org/10.1007/s12032-010-9577-1 PMid:20503107   Gu J, Liu Y, Kyritsis AP and Bondy ML (2009). Molecular epidemiology of primary brain tumors. Neurotherapeutics 6: 427-435. http://dx.doi.org/10.1016/j.nurt.2009.05.001 PMid:19560733   Haupt Y, Maya R, Kazaz A and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. http://dx.doi.org/10.1038/387296a0 PMid:9153395   Hunter SB, Abbott K, Varma VA, Olson JJ, et al. (1995). Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol. Exp. Neurol. 54: 57-64. http://dx.doi.org/10.1097/00005072-199501000-00007 PMid:7815080   Idbaih A, Boisselier B, Marie Y, Sanson M, et al. (2008). Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 1198: 16-20. http://dx.doi.org/10.1016/j.brainres.2008.01.027 PMid:18262501   Jeong BS, Hu W, Belyi V, Rabadan R, et al. (2010). Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 24: 1347-1353. http://dx.doi.org/10.1096/fj.09-146001 PMid:20019240   Jha P, Jha P, Pathak P, Chosdol K, et al. (2011). TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp. Mol. Pathol. 90: 167-172. http://dx.doi.org/10.1016/j.yexmp.2010.11.002 PMid:21115003   Khatri RG, Navaratne K and Weil RJ (2008). The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J. Neurosurg. 109: 842-848. http://dx.doi.org/10.3171/JNS/2008/109/11/0842 PMid:18976073   Kubbutat MH, Jones SN and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303. http://dx.doi.org/10.1038/387299a0 PMid:9153396   Kussie PH, Gorina S, Marechal V, Elenbaas B, et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953. http://dx.doi.org/10.1126/science.274.5289.948 PMid:8875929   Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, et al. (2008). TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet. Cytogenet. 180: 14-19. http://dx.doi.org/10.1016/j.cancergencyto.2007.08.019 PMid:18068527   Liu L, Wang K, Zhu ZM and Shao JH (2011). Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch. Med. Res. 42: 60-69. http://dx.doi.org/10.1016/j.arcmed.2011.01.008 PMid:21376265   Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97-109. http://dx.doi.org/10.1007/s00401-007-0243-4 PMid:17618441 PMCid:1929165   Malmer B, Feychting M, Lonn S, Ahlbom A, et al. (2005). p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol. Biomarkers Prev. 14: 2220-2223. http://dx.doi.org/10.1158/1055-9965.EPI-05-0234 PMid:16172235   Malmer BS, Feychting M, Lonn S, Lindstrom S, et al. (2007). Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J. Neurooncol. 82: 229-237. http://dx.doi.org/10.1007/s11060-006-9275-1 PMid:17151932   Marin MC, Jost CA, Brooks LA, Irwin MS, et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25: 47-54. http://dx.doi.org/10.1038/75586 PMid:10802655   Minelli C, Thompson JR, Abrams KR, Thakkinstian A, et al. (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37: 136-146. http://dx.doi.org/10.1093/ije/dym234 PMid:18037675   Ohgaki H, Dessen P, Jourde B, Horstmann S, et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64: 6892-6899. http://dx.doi.org/10.1158/0008-5472.CAN-04-1337 PMid:15466178   Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, et al. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860. http://dx.doi.org/10.1038/362857a0 PMid:8479525   Parhar P, Ezer R, Shao Y, Allen JC, et al. (2005). Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res. Mol. Brain Res. 137: 98-103. http://dx.doi.org/10.1016/j.molbrainres.2005.02.016 PMid:15950766   Pinto GR, Yoshioka FK, Silva RL, Clara CA, et al. (2008). Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 7: 207-216. http://dx.doi.org/10.4238/vol7-1gmr415 PMid:18393224   Rajaraman P, Wang SS, Rothman N, Brown MM, et al. (2007). Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev. 16: 1655-1661. http://dx.doi.org/10.1158/1055-9965.EPI-07-0314 PMid:17684142   Shete S, Hosking FJ, Robertson LB, Dobbins SE, et al. (2009). Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41: 899-904. http://dx.doi.org/10.1038/ng.407 PMid:19578367   Suzuki SO and Iwaki T (2000). Amplification and overexpression of mdm2 gene in ependymomas. Mod. Pathol. 13: 548-553. http://dx.doi.org/10.1038/modpathol.3880095 PMid:10824927   Tsuiki H, Nishi T, Takeshima H, Yano S, et al. (2007). Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol. Med. Chir. 47: 203-208. http://dx.doi.org/10.2176/nmc.47.203   Wang LE, Bondy ML, Shen H, El-Zein R, et al. (2004). Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64: 5560-5563. http://dx.doi.org/10.1158/0008-5472.CAN-03-2181 PMid:15313891   Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, et al. (2005). The molecular epidemiology of gliomas in adults. Neurosurg. Focus 19: E5. http://dx.doi.org/10.3171/foc.2005.19.5.6 PMid:16398469   Wrensch M, Jenkins RB, Chang JS, Yeh RF, et al. (2009). Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41: 905-908. http://dx.doi.org/10.1038/ng.408 PMid:19578366 PMCid:2923561   Yang M, Guo Y, Zhang X, Miao X, et al. (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28: 1996-2001. http://dx.doi.org/10.1093/carcin/bgm168 PMid:17638920   Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486. http://dx.doi.org/10.1002/ijc.22833 PMid:17546594